Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant what is the number needed to treat, number needed to harm and likelihood to be helped or harmed
International Journal of Clinical Practice,  Evidence Based Medicine  Clinical Article

Citrome L – Vilazodone represents another option for the treatment of major depressive disorder (MDD). Vilazodone appears to have a favourable weight–gain profile based on short–term studies. Sexual side–effects were not consistently demonstrated when assessed using clinical rating scales but spontaneously reported AEs related to sexual functioning were observed. Additional controlled data regarding long–term efficacy and effectiveness will help characterise this new agent when used in maintenance treatment.

Methods
  • The pivotal registration trials were accessed by querying , and for the search term `vilazodone'.
  • Product labeling provided additional information.
  • All available clinical reports of studies were identified.
  • Descriptions of the principal results and calculation of number needed to treat (NNT) and number needed to harm (NNH) for relevant dichotomous outcomes were extracted from the available study reports and other sources of information.

Results
  • Vilazodone is a specific serotonin reuptake inhibitor and serotonin 5HT1A receptor partial agonist.
  • In needs to be administered with food to ensure adequate bioavailability.
  • Approval for the treatment of MDD was based on a clinical development programme that included two 8–week placebo–controlled randomised clinical trials in outpatients with MDD where vilazodone was titrated to a target dose of 40mg/d over the first 2weeks.
  • Both trials evidenced efficacy for vilazodone as measured by the Montgomery Asberg Depression Rating Scale.
  • NNT for response vs. placebo was 8 (95% CI 6–16) and for remission was 14 (95% CI 8–55). NNH vs. placebo for discontinuation because of an adverse event (AE) was 27 (95% CI 15–104).
  • The most commonly encountered AEs (incidence ≥5% and at least twice the rate of placebo) were diarrhoea, nausea, vomiting and insomnia, with NNH values vs. placebo of 6 (95% CI 5–8), 6 (95% CI 5–8), 30 (95% CI 18–82) and 26 (95% CI 16–78), respectively.
  • NNH vs. placebo for any sexual AE was 12 (95% CI 9–18), but systematically collected data using rating scales of sexual function did not reveal treatment associated effects.
  • Vilazodone was not associated with clinically relevant weight change in the short–term trials.
  • In an open–label 1–year study of vilazodone, mean weight increased by 1.7kg among the observed cases.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharmacy

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharmacy Articles

1 New drug could make vaccines more effective in the elderly University of Oxford News, November 14, 2014

2 FDA approves new type of sleep drug, Belsomra Full Text FDA Press Announcements, August 14, 2014    Free full text

3 Antibiotic developed 50 years ago may be the key to fighting 'superbugs' University at Buffalo Health and Medicine News, June 19, 2014

4 One injection stops diabetes in its tracks Salk Institute News, July 18, 2014

5 'Unsung' cells double the benefits of a new osteoporosis drug Johns Hopkins Medicine, October 7, 2014

6 New research indicates statin drugs must be taken properly Michigan State University Health News, July 22, 2014

7 Statins reverse learning disabilities caused by genetic disorder UCLA Health System, November 18, 2014

8 UCLA researchers find that drug used for another disease slows progression of Parkinson's UCLA Health System, October 10, 2014

9 Opioid overdose cause for over 100,000 emergency department visits in 2010 Lifespan, November 12, 2014

10 Semen directly impairs effectiveness of microbicides that target HIV Gladstone Institutes News, November 14, 2014

11 Duke team brings life-saving function to ketchup packets Duke University Health & Medicine News, July 3, 2014

12 A new pathway discovered regulating autoimmune diseases Brigham and Women's Hospital, October 9, 2014

13 Effect of ginger (Zingiber officinale) on heavy menstrual bleeding: a placebo-controlled, randomized clinical trial Phytotherapy Research, October 13, 2014    Clinical Article

14 Daily aspirin use and prostate cancer–specific mortality in a large cohort of men with nonmetastatic prostate cancer Journal of Clinical Oncology, October 24, 2014    Clinical Article

15 High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection Clinical Gastroenterology and Hepatology , November 24, 2014    Clinical Article

16 Ripasudil: first global approval Drugs, November 21, 2014    Clinical Article

17 Effect of prasugrel in patients with asthma: results of PRINA,a randomized, double-blind, placebo-controlled, cross-over study Journal of Thrombosis and Haemostasis, November 25, 2014

18 Nebivolol, but not metoprolol, lowers blood pressure in nitric oxide–sensitive human hypertension Hypertension, November 24, 2014    Clinical Article

19 Magnesium should be given to all children presenting to hospital with acute severe asthma Paediatric Respiratory Reviews, October 15, 2014    Clinical Article

20 Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients American Journal of Transplantation, November 17, 2014    Clinical Article

Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacistmore